Because the AKTi treatment increased the phosphorylation of RTKs in the KRAS or BRAF mutant CRC cells, we hypothesized that the combination of RTKis and AKTi might inhibit the cell growth more efficiently. Here, KRAS is linked to colorectal carcinoma.